Abstract：
In a previous vaccination study in pigs, heterologous prime-boost vaccination with whole-inactivated H1N1 virus vaccines (WIV) induced superior antibody responses and protection compared to homologous prime-boost vaccination. However, no pan-H1 antibody response was induced. Therefore, to stimulate both local and systemic immune responses, we first vaccinated pigs intranasally with a pseudorabies vector vaccine expressing the pH1N1 hemagglutinin (prvCA09) followed by a homologous or heterologous WIV booster vaccine. Homologous and heterologous WIV-WIV vaccinated groups and mock-vaccinated or prvCA09 single-vaccinated pigs served as control groups. Five weeks after the second vaccination, pigs were challenged with a homologous pH1N1 or one of two heterologous H1N2 swine influenza A virus strains. A single prvCA09 vaccination resulted in complete protection against homologous challenge, and vector-WIV vaccinated groups were significantly better protected against heterologous challenge compared to the challenge control group or WIV-WIV vaccinated groups. Furthermore, vector-WIV vaccination resulted in broader hemagglutination inhibition antibody responses compared to WIV-WIV vaccination and higher numbers of antibody-secreting cells in peripheral blood, draining lymph nodes and nasal mucosa. However, even though vector-WIV vaccination induced stronger antibody responses and protection, we still failed to induce a pan-H1 antibody response.
摘要：
在之前的猪疫苗接种研究中，与同源初免-加强疫苗接种相比,使用全灭活H1N1病毒疫苗(WIV)的异源初免-加强疫苗接种诱导优异的抗体应答和保护。然而,未诱导pan-H1抗体应答。因此,刺激局部和全身免疫反应，我们首先在猪鼻内接种表达pH1N1血凝素(prvCA09)的伪狂犬病载体疫苗,然后接种同源或异源WIV加强疫苗.同源和异源WIV-WIV疫苗接种组和模拟疫苗接种或prvCA09单次疫苗接种的猪作为对照组。第二次疫苗接种五周后，用同源pH1N1或两种异源H1N1猪甲型流感病毒株之一攻击猪。一次prvCA09疫苗接种可完全防止同源攻击，与攻击对照组或WIV-WIV疫苗接种组相比,载体-WIV疫苗接种组对异源攻击的保护显著更好。此外，与WIV-WIV疫苗接种相比，载体-WIV疫苗接种导致更广泛的血凝抑制抗体反应，并且外周血中更多的抗体分泌细胞，引流淋巴结和鼻粘膜。然而,即使载体-WIV疫苗接种诱导更强的抗体反应和保护，我们仍然未能诱导pan-H1抗体反应。
